R L Heilman
Affiliation: Mayo Clinic
- Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipientsR L Heilman
Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ
Am J Transplant 10:563-70. 2010..In a multivariate analysis, patients in groups 2 or 3 had a higher risk of IF/TA score > 2 on the 1-year biopsy (OR 6.62, 95% CI 2.68-16.3). We conclude that SCI and SAR increase the risk of developing IF/TA in patient on RSW...
- Impact of acute rejection on kidney allograft outcomes in recipients on rapid steroid withdrawalR L Heilman
Department of Medicine, Mayo Clinic, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
J Transplant 2011:583981. 2011..06, 95% CI 3.39-24.2) and between the SR and control group (HR 4.22, 95% CI 1.30-13.7). Conclusion. Both SR and CR are associated with an inferior graft survival in recipients on RSW...
- Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawalRaymond L Heilman
Department of Medicine, Mayo Clinic, Phoenix, AZ 85054, USA
Transplantation 93:47-53. 2012..Calcineurin-inhibitor therapy is a contributing factor to the origin of interstitial fibrosis and tubular atrophy (IFTA)...
- Immunosuppression in simultaneous pancreas-kidney transplantation: progress to dateRaymond L Heilman
Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona 85054, USA
Drugs 70:793-804. 2010..Recent analysis of registry data shows that most transplant centres are using an induction agent followed by a combination of tacrolimus, MMF and corticosteroids in SPKT recipients...
- Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawalRaymond L Heilman
Department of Medicine, Mayo Clinic in Arizona, Phoenix, AZ 85054, USA
Transplantation 92:767-73. 2011..The use of calcineurin inhibitors is associated with chronic nephrotoxicity and lower glomerular filtration rate (GFR). As a result, one strategy of transplant immunosuppression is calcineurin inhibitor elimination...
- Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppressionRaymond L Heilman
Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
Clin Transplant 22:309-15. 2008..Recent studies have documented good patient and graft outcomes and a low risk of acute rejection with steroid-avoidance immunosuppression in kidney-transplant recipients, but the risk of progressive graft fibrosis is not well studied...
- Steroid avoidance immunosuppression in low-risk kidney transplant recipientsR L Heilman
Division of Nephrology, Mayo Clinic Hospital, Kidney and Pancreas Program and Mayo Clinic College of Medicine, Phoenix, Arizona 85054, USA
Transplant Proc 37:1785-8. 2005..8% and 96.8%, respectively. SA with anti-thymocyte globulin induction in low-immunologic risk kidney transplant recipients is safe and is associated with a low risk of BPAR. The incidence of PTDM appears to be lower...
- Outcomes after simultaneous pancreas and kidney transplantation and the discriminative ability of the C-peptide measurement pretransplant among type 1 and type 2 diabetes mellitusH A Chakkera
Mayo Clinic, Scottsdale, Arizona, USA
Transplant Proc 42:2650-2. 2010..However, because the kidney is the major site for C-peptide catabolism, C-peptide is unreliable to discriminate the type of diabetes in patients with kidney disease...
- Genetic differences in Native Americans and tacrolimus dosing after kidney transplantationH A Chakkera
Division of Nephrology, Mayo Clinic, Phoenix, Arizona 85054, USA
Transplant Proc 45:137-41. 2013..Native Americans required significantly lower tacrolimus doses than Caucasians to achieve similar tacrolimus trough levels, in part due to lower tacrolimus clearance from decreased drug metabolism and excretion...
- Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximabR L Heilman
Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, Arizona 85259, USA
Transplant Proc 38:1307-13. 2006..001). Median time to biopsy-proven acute rejection was 27 and 71 days, respectively. The low incidence of biopsy-proven acute rejection with steroid-avoidance immunosuppression may be further reduced with antithymocyte globulin...
- Deceased donor kidney transplantation from donors with acute renal failure due to rhabdomyolysisK L Mekeel
Division of Transplantation, Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, AZ, USA
Am J Transplant 9:1666-70. 2009..3 (0.7-1.8). In conclusion, our experience suggests that rhabdomyolysis with acute renal failure should not be a contraindication for donation, although recipients may experience slow or delayed graft function...
- Diffuse parenchymal urine leak after kidney transplantation following degloving injury during donor nephrectomyK L Mekeel
Department of Transplant Surgery, Mayo Clinic, Phoenix, AZ, USA
Am J Transplant 7:2039-41. 2007..The patient was successfully treated with tissue glue treatment to the kidney surface and peritoneal window...
- Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantationH A Chakkera
Division of Transplantation Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85259, Arizona, USA
Transplant Proc 41:4172-7. 2009..Several genetic polymorphisms have been shown to be associated with T2DM. We hypothesized that transplant recipients who carry risk alleles for T2DM are "tipped over" to develop diabetes mellitus in the posttransplant milieu...
- Successful transplantation of a split crossed fused ectopic kidney into a patient with end-stage renal diseaseKristin L Mekeel
Division of Transplant, Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Phoenix, AZ 85054, USA
J Transplant 2010:383972. 2010..The transplant was uncomplicated, and the graft had immediate function. The patient is now two years from transplant with excellent function...
- Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trialH Amer
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Am J Transplant 13:1576-85. 2013..Moderate renal allograft fibrosis was reduced in treated patients. Oral paricalcitol is effective in decreasing posttransplant hyperparathyroidism and may have beneficial effects on renal allograft histology...
- Kluyvera co-infection in two solid organ transplant recipients: an emerging pathogen or a colonizer bystander?R Cheruvattath
Division of Transplantation Medicine, Mayo Clinic Hospital, Phoenix, AZ 85054, USA
Transpl Infect Dis 9:83-6. 2007..The isolation of Kluyvera as a pathogen in transplant patients emphasizes that this commensal organism may be virulent in this patient population...
- Coccidioidomycosis after renal transplantation in an endemic areaC M Braddy
Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA
Am J Transplant 6:340-5. 2006..Treatment for acute rejection and induction with antithymocyte globulin did not appear to increase the risk of subsequent coccidioidomycosis...
- Early detection of acute renal failure by serum cystatin C: a new opportunity for a hepatologistMarek J Mazur
Transplant Medicine and Nephrology, Mayo Clinic Hospital, Phoenix, AZ, USA
Liver Transpl 11:705-7. 2005